Meda's Astepro receives registration approval in Europe

Download PDF Copy

Mar 21 2012

NewsGuard 100/100 Score

Astepro (STO:MEDAA) has received registration approval in Europe via the decentralized procedure. Astepro is a new nasal spray for the treatment of allergic rhinitis. National registration processes, including price and reimbursement, will now follow in each country. Launch is expected next year.

"We are pleased to announce the approval of Astepro in Europe. The product has been launched in the US with good success. With the addition of Dymista (currently in registration phase) Meda will have an extraordinary strong position in the allergy rhinitis area, both in the US and Europe", said Anders Lönner, CEO of Meda AB.

Source:

MEDA

Posted in: Medical Condition News | Pharmaceutical News

Tags: Allergic Rhinitis, Allergy, Nasal Spray, Rhinitis

Comments (0)

Download PDF Copy

Suggested Reading

How does the season of birth influence the risk of asthma and allergic rhinitis?

How does the season of birth influence the risk of asthma and allergic rhinitis?

Home dust chemicals predict asthma and allergies in children

Home dust chemicals predict asthma and allergies in children

Stapokibart shows promise in reducing nasal congestion in seasonal allergy patients, study finds

Stapokibart shows promise in reducing nasal congestion in seasonal allergy patients, study finds

Study shows engineered antibodies significantly boost Omicron neutralization

Study shows engineered antibodies significantly boost Omicron neutralization

New dry powder aerosol COVID-19 vaccine shows promise against multiple virus strains

New dry powder aerosol COVID-19 vaccine shows promise against multiple virus strains

Research confirms no association between SARS-CoV-2 and childhood asthma diagnoses

Research confirms no association between SARS-CoV-2 and childhood asthma diagnoses

Finnish study links autumn and winter births to higher rates of asthma and allergic rhinitis

Finnish study links autumn and winter births to higher rates of asthma and allergic rhinitis

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Can olfactory loss predict disease? Study ties loss of smell to 139 health conditions